Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03838484 · ClinicalTrials.gov registry record · NA
Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia
A NA study, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT03838484 is a NA study that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 18 participants.
The verdict
NCT03838484, a NA study, was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether nicotine, a drug that activates receptors called nicotinic acetylcholine receptors in the brain, improves the ability to make or withhold responses to faces that are either emotionally neutral or emotionally negative. This study will also test whether the drug affects brain activity while making or withholding responses using electroencephalography. Previous studies in people with schizophrenia have shown that more errors in response to negative emotional cues are related to greater likelihood of impulsive aggressive behavior. Therefore, the aim of this study is to determine whether nicotine might be a new strategy to reduce aggressive behavior. The investigators' goal is 25 individuals with schizophrenia and 25 healthy controls to complete the study at Vanderbilt.
Interventions
- DRUG Placebo patch
- DRUG Nicotine Patch, 7 Mg/24 Hr
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-05-10 |
| Est. Completion | 2020-02-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03838484
The ClinicalTrials.gov registry entry for NCT03838484 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo patch is the first listed.
NCT03838484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03838484 about?
NCT03838484 is a clinical study titled "Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia". The purpose of this study is to test whether nicotine, a drug that activates receptors called nicotinic acetylcholine receptors in the brain, improves the ability to make or withhold responses to faces that are either emotionally neutral or emotionally negative. This study will also test whether the...
What is the current status of trial NCT03838484?
This trial is currently terminated. It is a NA study. The enrollment target is 18 participants. The study started on 2019-05-10. Estimated completion is 2020-02-24.
What interventions are being tested in trial NCT03838484?
The interventions under investigation include: Placebo patch (DRUG), Nicotine Patch, 7 Mg/24 Hr (DRUG).
Who is sponsoring clinical trial NCT03838484?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.